When a room of physicians at ASH 2024 was asked whether they had prescribed a gene therapy in a commercial context, only a handful said yes.

As countries in the Northern hemisphere deal with the flu season, experts say regulation surrounding flu vaccines could be due for a shake up with new healthcare leaders set to take charge in the US.

FHD-286 is a small molecule commercialized by Foghorn Therapeutics, with a leading Phase I program in Myelodysplastic Syndrome.

Conduit Pharmaceuticals has signed an agreement with Sarborg to leverage advanced AI and cybernetics for the optimisation of processes related to key drug development. These include the repurposing ...

ADCT-602 is a monoclonal antibody conjugated commercialized by ADC Therapeutics, with a leading Phase II program in B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia).

Puberty blockers for people aged under 18 with gender dysphoria will be indefinitely banned by the UK Government.

LNA-043 is under development for the treatment of osteoarthritis. It is administered intra-articularly. The drug candidate acts by targeting angiopoietin related protein 3 (ANGPTL3). It is a new ...

The push to replace Albert Bourla as Pfizer’s CEO drew attention from the pharma industry but was soon derailed by several events.

Meitheal Pharmaceuticals has gained exclusive US commercial rights for XENLETA for treating CABP in the adult population.

Bexotegrast is a small molecule commercialized by Pliant Therapeutics, with a leading Phase III program in Idiopathic Pulmonary Fibrosis.

TOUR-006 is a monoclonal antibody commercialized by Tourmaline Bio, with a leading Phase II program in Graves' Ophthalmopathy.

Olafertinib is a small molecule commercialized by Fortress Biotech, with a leading Phase II program in Non-Small Cell Lung Cancer.